Imunon, Inc. (IMNN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Imunon reported revenue of $0. Net income was -$14.5M, or -$6.83 per diluted share. Operating activities generated -$13.9M of cash, leaving -$14.2M of free cash flow. At fiscal year end, Imunon held $12.3M in total assets against $5.2M in total liabilities, including $8.8M of cash and equivalents.
Open the full interactive Imunon financials → Quarterly statements, key ratios, valuation history and price charts.
Imunon Key Stats
| Share Price | $1.07 |
|---|---|
| Market Cap | $5.6M |
| 52-Week Range | $1.07 – $5.10 |
| Shares Outstanding | 5.2 million (basic, 2026 Q2) |
Imunon Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $500,000 | $500,000 | $500,000 | — | $0 | $0 |
| Operating Income | -$18.5M | -$21.0M | -$24.9M | -$21.0M | -$19.1M | -$14.7M |
| Pre-Tax Income | -$23.3M | -$22.2M | -$37.5M | -$20.8M | -$18.6M | $14.5M |
| Income Tax | -$1.8M | -$1.4M | -$1.6M | -$1.3M | — | $29.0M |
| Net Income | -$21.5M | -$20.8M | -$35.9M | -$19.5M | -$18.6M | -$14.5M |
| Diluted EPS | -$131.09 | -$49.96 | — | -$28.17 | -$21.13 | -$6.83 |
Imunon Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$3.4M | -$4.2M | -$4.2M | -$2.8M |
| Diluted EPS | -$1.16 | -$1.99 | -$0.84 | -$0.54 |
Imunon Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $17.2M | $19.6M | $11.5M | $5.8M | $5.9M | $8.8M |
| Current Assets | $18.8M | $51.9M | $37.2M | $18.2M | $8.0M | $10.7M |
| Total Assets | $37.5M | $74.0M | $44.0M | $21.9M | $9.7M | $12.3M |
| Current Liabilities | $6.8M | $6.8M | $10.0M | $7.4M | $4.8M | $4.6M |
| Total Long-Term Debt | $5.1M | $5.9M | $6.0M | — | — | — |
| Total Liabilities | $18.9M | $18.3M | $14.6M | $8.5M | $5.5M | $5.2M |
| Shareholders' Equity | $18.6M | $55.8M | $29.3M | $13.4M | $4.2M | $7.1M |
Imunon Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$15.6M | -$16.2M | -$23.1M | -$19.0M | -$18.9M | -$13.9M |
| Cash From Investing | $7.9M | -$30.1M | $8.3M | $11.0M | $9.8M | -$280,572 |
| Cash From Financing | $18.0M | $54.8M | $6.7M | -$3.6M | $9.1M | $17.1M |
| Free Cash Flow | -$15.6M | -$16.5M | -$23.4M | -$19.5M | -$18.9M | -$14.2M |
Figures from Imunon's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Imunon financials page for every line item.
Imunon Company Profile
| Ticker | IMNN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Lawrenceville, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000749647 |
Frequently Asked Questions
What was Imunon's revenue in fiscal 2025?
Imunon (IMNN) reported revenue of $0 for fiscal 2025.
What is Imunon's annual revenue history?
Imunon's annual revenue by fiscal year: 2020: $500,000; 2021: $500,000; 2022: $500,000; 2024: $0; 2025: $0.
What was Imunon's net income in fiscal 2025?
Imunon reported net income of -$14.5M for fiscal 2025.
What was Imunon's earnings per share (EPS) in fiscal 2025?
Imunon's diluted EPS was -$6.83 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Imunon generate in fiscal 2025?
Imunon generated -$14.2M of free cash flow in fiscal 2025.
What was Imunon's revenue last quarter?
In its most recent reported quarter (2026 Q2), Imunon reported revenue of $0.
How many shares of Imunon are outstanding?
Imunon reported a weighted average of 5.2 million basic shares outstanding in 2026 Q2.
What is Imunon's market cap?
Based on its latest closing price, Imunon (IMNN) has a market capitalization of about $5.6M.
When does Imunon's fiscal year end?
Imunon's fiscal year end, as registered with the SEC, is December 31.
Where is Imunon headquartered?
Imunon lists its business address in Lawrenceville, New Jersey in its SEC filings.